Study of β-cyclodextrin and ethylated β-cyclodextrin salbutamol complexes, in vitro evaluation of sustained-release behaviour of salbutamol

International Journal of Pharmaceutics

Volumn 141, Issue 1-2, 1996, Pages 117-124

  Lemesle Larnache, Véronique ^a   Wouessidjewe, Denis ^a   Chéron, Monique ^b   Duchêne, Dominique ^a  

^a UNIV PARIS SUD   (France)

^b CNRS   (France)

Author keywords

Circular dichroism; Differential; Dissolution behaviour; Electrospray mass spectrometry; Ethylated cyclodextrin; Inclusion complexes; Salbutamol; Scanning calorimetry; Cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; KLEPTOSE; SALBUTAMOL; UNCLASSIFIED DRUG;

ARTICLE; CIRCULAR DICHROISM; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; FREEZE DRYING; MASS SPECTROMETRY; PRIORITY JOURNAL; SOLUBILITY; SUSTAINED RELEASE PREPARATION;

EID: 0030572688     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(96)04624-8     Document Type: Article

References (32)

1. Arias, M.J., Ginés, J.M., Moyano, J.R., Sànchez-Soto, P.J., Ruiz-Conde, A., Novak, C. and Rabasco, A.M., Interaction of triamterene with hydroxypropyl β-cyclodextrin in ground mixtures, improvement in the dissolution properties. Proc. 1st World Meeting APGI APV, Budapest. Hungary, 1995, pp. 607-608.
2. Bates, P.S., Parker, D. and Green, B.N., Characterisation of the complexation behaviour of lipophilic cyclodextrins by electrospray mass spectrometry. J. Chem. Soc., Chem. Commun. (1993) 693-696.
3. Buss, V., Circular dichroism study of the cyclodextrin-mediated aggregation of cyanine dyes. In Hedges, R. (Ed). Minutes 6th Int. Symp. Cyclodextrins. Chicago, 21-24 April. Editions de Santé. Paris. 1992. pp. 160-165.
4. Cabral Marques, H.M., Hadgraft, J. and Kellaway, I.W., Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int. J. Pharm., 63 (1990a) 259-266.
5. 1H-NMR evidence for the salbutamol-β-cyclodextrin complex. Int. J. Pharm., 63 (1990b) 267-274.
6. Castelli, F., Puglisi, G., Pignatello, R. and Gurriere, S., Calorimetric studies of the interaction of 4-biphenylacetic acid and its β-cyclodextrin inclusion compound with lipid model membrane. Int. J. Pharm., 52 (1989) 115-121.
7. Chun, I.N. and Yun, D.S., Inclusion complexation of hydrocortisone butyrate with cyclodextrins and dimethyl-β-cyclodextrin in aqueous solution and in solid state. Int. J. Pharm., 96 (1993) 91-103.
8. Djedaïni, F., Lin, S.Z., Perly, B. and Wouessidjewe, D., High field NMR techniques for the investigation of a β-cyclodextrin-indomethacin complex. J. Pharm. Sci., 79 (1990) 643-646.
9. Drabowicz, J., Dudzinski, B., Mikolajczyk, M. and Sochacki, M., A study of β-cyclodextrin inclusion complexes with optically active alkyl p-tolyl sulfoxides by fast atom bombardment mass spectrometry. Pol. J. Chem., 68 (1994) 2265-2270.
10. Duchêne, D. and Wouessidjewe, D., Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev. Ind. Pharm., 16 (1990) 2487-2499.
11. Duchêne, D., Glomot, F. and Vauthion, C., Pharmaceutical applications of cyclodextrins. In Duchêne, D. (Ed), Cyclodextrins and Their Industrial Uses. Editions de Santé, Paris, 1986. pp. 211-257.
12. El-Gendy, G.A. and El-Gendy, M.A., Heptakis (2,6-di-O-methyl)-β-cyclodextrin complexation. Eur. J. Pharm. Biopharm., 39 (1993) 249-254.
13. Hirayama, F. and Uekama, K., Methods of investigation and preparing inclusion compounds. In Duchêne, D. (Ed), Cyclodextrins and Their Industrial Uses. Editions de Santé, Paris. 1986, pp. 131-172.
14. Hirayama, F., Wang, Z. and Uekama, K., Effect of 2-hydroxypropyl-β-cyclodextrin on crystallization and polymorphic transition of nifedipine in solid state. Pharm. Res., 11 (1994) 1766-1770.
15. Hiriochi, K., Hirayama, F. and Uekama, K., Slow release characteristics of diltiazem from ethylated-β-cyclodextrin complexes. J. Pharm, Sci., 79 (1990) 128-132.
16. Jones, S.P., Grant, D.J.W., Hadgraft, J. and Parr, G.D., Cyclodextrins in the pharmaceutical sciences. Part I: preparation, structure and properties of cyclodextrins and cyclodextrin inclusion compounds. Acta Pharm. Tech., 30 (1984) 213-223.
17. Kawahara, K., Ueda, H., Tomono, K. and Nagai, T., Effect of diethyl β-cyclodextrin on the release and absorption behaviour of indomethacin from ointment bases. STP Phama Sci., 6 (1992) 506-513.
18. Lemesle-Lamache, V., Taverna, M., Wouessidjewe, D., Duchêne, D. and Ferrier, D., Binding constant determination of salbutamol to unmodified and ethylated-cyclodextrins by affinity electrophoresis. J. Chromatogr. A. in press.
19. Metzger, J.W., Jung, M., Schmalzing, D., Bayer, E. and Schurig, V., Analysis of cyclomalto-oligosaccharides (cyclodextrins) and derivatives thereof by ion-spray mass spectrometry. Carbohydr. Res., 222 (1991) 23-35.
20. Müller, B.W. and Brauns, U., Hydroxypropyl-β-cyclodextrin derivatives: influence of average degree of substitution on complexing ability and surface activity. J. Pharm. Sci., 75 (1986) 571-572.
21. Pitha, J., Harman, M. and Michel, M.E., Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. J. Pharm. Sci., 75 (1986) 165-167.
22. emc Congr. Int. Technologie Pharmaceutique, V. Paris, 1992, pp. 423-430.
23. Szejtli, J., Limits of cyclodextrin application in oral drug preparations. J. Ind. Phenom., 2 (1984) 487-501.
24. Szejtli, J., Cydodextrins in drug formulation: Part I. Pharm. Tech. Int., Feb. (1991) 15-22.
25. Ueda, H. and Nagai, T., Nuclear magnetic resonance (NMR) spectroscopy of inclusion compounds of tolbutamide and chlorpropamide with β-cyclodextrin in aqueous solution. Chem. Pharm. Bull., 28 (1980) 1415-1421.
26. Uekama, K., Pharmaceutical applications of methylated cyclodextrins. Pharm. Int., 3 (1985) 61-65.
27. Uekama, K., Hirashima, N., Horiuchi, Y., Hirayama, F., Ijitsu, F. and Ueno, M., Ethylated β-cyclodextrins as hydrophobic drug carriers: sustained release of diltiazem in the rat. J. Pharm. Sci., 76 (1987) 660-661.
28. Uekama, K., Arima, H., Irie, T., Matsubara, K. and Kuriki, T., Sustained release of buserelin acetate, a luteinizing hormone-releasing hormone agonist, from an injectable oily preparation utilizing ethylated β-cyclodextrin. J. Pharm. Pharmacol., 41 (1989) 874-876.
29. Uekama, K., Hirayama, F. and Irie, T., Pharmaceutical uses of cyclodextrin derivatives. In Szycher, M. (Ed), Lancaster, High Performance Biomaterials, Technomic, 1991, pp. 790-806.
30. Umemura, M., Ueda, H., Tomono, K. and Nagai, T., Effect of diethyl-β-cyclodextrin on the release of nitroglycerin from formulations. Drug Des. Del., 6 (1990) 297-310.
31. Vollmer, U., Müller, B.W., Mesens, J., Wilffert, B. and Peters, T., In vivo skin pharmacokinetics of liarozole: percutaneous absorption studies with different formulations of cyclodextrin derivatives in rats. Int. J. Pharm., 99 (1993) 51-58.
32. Wouessidjewe, D., Crassous, A., Duchêne, D., Coleman, A., Rysanek, N., Tsoucaris, G., Perly, B. and Djedaïni, F., Inclusion of spironolactone in cyclomaltoheptaose: a guest affected by the hospitality of the host. Carbohydr. Res., 192 (1989) 313-322.